Financial Analysis: Amarantus Bioscience (OTCMKTS:AMBS) & Surgery Partners (NASDAQ:SGRY)

Amarantus Bioscience (OTCMKTS:AMBS) and Surgery Partners (NASDAQ:SGRY) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, dividends, valuation, earnings, profitability and analyst recommendations.

Profitability

This table compares Amarantus Bioscience and Surgery Partners’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Amarantus Bioscience	N/A	N/A	N/A
Surgery Partners	-2.63%	0.87%	0.34%

Valuation & Earnings

This table compares Amarantus Bioscience and Surgery Partners”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Amarantus Bioscience	N/A	N/A	N/A	N/A	N/A
Surgery Partners	$3.31 billion	0.60	-$77.90 million	($0.70)	-21.83

Amarantus Bioscience has higher earnings, but lower revenue than Surgery Partners.

Risk and Volatility

Amarantus Bioscience has a beta of 1.52, meaning that its stock price is 52% more volatile than the S&P 500. Comparatively, Surgery Partners has a beta of 1.91, meaning that its stock price is 91% more volatile than the S&P 500.

Analyst Ratings

This is a breakdown of current ratings for Amarantus Bioscience and Surgery Partners, as provided by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Amarantus Bioscience	0	0	0	0	0.00
Surgery Partners	1	3	7	0	2.55

Surgery Partners has a consensus price target of $19.45, suggesting a potential upside of 27.32%. Given Surgery Partners’ stronger consensus rating and higher probable upside, analysts plainly believe Surgery Partners is more favorable than Amarantus Bioscience.

Summary

Surgery Partners beats Amarantus Bioscience on 7 of the 8 factors compared between the two stocks.

About Amarantus Bioscience

Amarantus BioScience Holdings, Inc., a biopharmaceutical company, focuses on the development of diagnostic and therapeutic product candidates in the areas of neurology, psychiatry, ophthalmology, and regenerative medicine. The company's diagnostic products in development include the lymphocyte proliferation (LymPro) test, a diagnostic blood test for Alzheimer's disease; and MSPrecise, a proprietary DNA sequencing assay for the identification of patients with multiple sclerosis. Its therapeutic products in development comprise Eltoprazine, a small molecule drug for the treatment of Parkinson's disease Levadopa-Induced Dyskinesia and attention deficit hyperactivity disorders; and mesencephalic-astrocyte-derived neurotrophic factor for the treatment of various animal models, including retinitis pigmentosa and retinal artery occlusion. It also develops NuroPro, a neurodegenerative disease diagnostic platform with application in Parkinson's disease; BC-SeraPro, an oncology diagnostic platform with application in breast cancer; and PhenoGuard platform for neurrotrophic factor discovery. In addition, the company develops Engineered Skin Substitute (ESS), a cell therapy-based autologous skin replacement product that is in mid-stage clinical development for the treatment of life-threatening severe burns. Amarantus BioScience Holdings, Inc. has a cooperative research and development agreement with the U.S. Army Institute of Surgical Research and Rutgers University. The company was formerly known as Amarantus Bioscience, Inc. and changed its name to Amarantus BioScience Holdings, Inc. in April 2013. Amarantus BioScience Holdings, Inc. was founded in 2008 and is headquartered in New York, New York.

About Surgery Partners

Surgery Partners, Inc., together with its subsidiaries, owns and operates a network of surgical facilities and ancillary services in the United States. The company provides ambulatory surgery centers and surgical hospitals that offer non-emergency surgical procedures in various specialties, including orthopedics and pain management, ophthalmology, gastroenterology, and general surgery. It offers diagnostic imaging, laboratory, obstetrics, oncology, pharmacy, physical therapy, and wound care; and ancillary services, including multi-specialty physician practices, urgent care facilities, and anesthesia services. In addition, it offers single- and multi-specialty facilities. Surgery Partners, Inc. was founded in 2004 and is headquartered in Brentwood, Tennessee.